Observational Study of HA380 Blood Perfusion Adsorption Combined with Continuous Renal Replacement Therapy in the Treatment of Sepsis

Methods: Forty septic patients who underwent CRRT in our hospital from February 1, 2023 to December 31, 2023 were selected as the study subjects. Based on the sequential admission numbers of the patients, they were randomly divided into a treatment group (TM group) and a control group (Ctrl group), with 20 patients in each group. Both groups of patients received standard treatment and continuous veno-venous hemofiltration (CVVH) until hemodynamic stability was achieved. On this basis, the TM group was accompanied with HA380 BPA therapy, administered at least once within 24 hours of admission, with each perfusion lasting 4 hours, once a day, for a total of 3 times. Statistical analysis was conducted to assess changes in clinical indicators before and after treatment in two patient groups, including rates of adverse events, bleeding events, and the 28-day mortality rate.

研究方法：本研究选取了2023年2月1日至2023年12月31日期间在我院接受连续性血液净化治疗（CRRT）的四十例脓毒症患者作为研究对象。根据患者的入院顺序编号，将患者随机分为治疗组（TM组）和对照组（Ctrl组），每组各20例。两组患者均接受标准治疗及连续性静脉-静脉血液滤过（CVVH），直至达到血流动力学稳定。在此基础上，TM组患者在入院后24小时内至少接受一次HA380 BPA治疗，每次灌注持续4小时，每日一次，连续治疗3次。通过对两组患者治疗前后临床指标的变化进行统计分析，评估了不良反应发生率、出血事件发生率和28天死亡率等指标的变化。